Tip os
Log ind
22856712.jpg
Foto: Martin Slottemo Lyngstad

BioPorto targets prominent new board member

Top picks in English:

Diagnostics company BioPorto proposes a prominent biotech profile and former CEO of the company Symphogen as a new member of its board of directors, to be officially elected at its general meeting in April.


BY ELIZABETH MØNSTED JOHANSEN
Offentliggjort 20.03.17 kl. 11:46

Log ind for at læse artikler

Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.

Prøv os gratis i 14 dage

Få fuld adgang til vores kvalitetsjournalistik med et gratis prøveabonnement.

Sign up for MedWatch newsletter
Mest læste Top picks in English

Novo chief: ”This is data the world has never seen before”

Mads Krogsgaard Thomsen Top picks in English:

Strong phase II data from Novo Nordisk’s pipeline-hope semaglutide gives cause for optimism for chief science officer Mads Krogsgaard Thomsen, who believes Novo holds a new generation of obesity medicine.

Lundbeck executive: I knew FDA had another opinion

Top picks in English:

It is yet uncertain whether Lundbeck, for the third time, will try to win an updated label for antidepressant Trintellix in the US, says Anders Gersel Pedersen, Lundbeck’s executive vice president for research and development. Last week's rejection from FDA came as no surprise to him.

Here is what Danish drug companies pay their workers

Top picks in English:

The average monthly salary in the private pharmaceutical industry in Denmark is DKK 57,109. Make the jump to find out which company pays the highest wages and learn how much the rest of the industry pays as well.

Danish hearing aid giants in global showdown

Top picks in English:

The world’s largest hearing device dealer, Amplifon, expresses concern over the entry into the retail market of manufacturers such as William Demant. GN Resound, on the other hand, receives praise and is expected to form even closer ties to its Italian collaborator.

Goodbye to Novo A/S

Top picks in English:

In order to avoid confusion, Novo A/S, the holding company of Novo Nordisk and Novozymes and one of Denmark’s major life science investors, has decided to change its name.

New DTU tablet can pave the way for oral insulin

Top picks in English:

With a new type of tablet, scientists at the Technical University of Denmark (DTU) hope to do what Novo Nordisk was not capable of – to deliver insulin orally so diabetes patients will not need to inject themselves. Professor Anja Boisen reveals that DTU has already initiated a dialogue with a number of drug companies, including Novo.

Forsiden lige nu

Analyse: Bavarians nye milliardaftale bør få spekulanterne til at ryste i bukserne

POLFOTO_46554039.jpg Medicinal & Biotek:

Biotekselskabet Bavarian Nordic viser endnu engang, at selskabet er ved at udvikle sig til et selskab, der er meget mere end bare det store kræfthåb Prostvac.

AZ indgår kæmpeaftale med Merck efter fejlet kræftstudie

Medicinal & Biotek:

Britiske AstraZeneca og amerikanske Merck har torsdag indgået en samarbejdsaftale på kræftområdet, som har en potentiel værdi på et tocifret milliardbeløb. Det sker samme dag, som et imødeset lungekræftstudie fra AstraZeneca fejlede og skar milliarder af selskabets markedsværdi.

Bavarian-direktør: Ny aftale rangerer højt målt på potentialet

Medicinal & Biotek:

Bavarian Nordic håber at modtage første milepælsbetaling fra nyt samarbejde med Janssen inden for et par år.

Celgene indgår forlig i whistleblower-sag

Medicinal & Biotek:

Selvom Celgene afviser at have markedsført Thalomid og Revlimid til anden brug end den godkendte, indgår virksomheden forlig.

Neurosearch: Salg til Saniona var eneste mulighed

Medicinal & Biotek:

Der var ikke andre seriøse bejlere til at overtage rettighederne til en række projekter fra Neurosearch, siger topchef Allan Andersen om salget til Saniona, der for 5,5 mio. kr. køber sig fri for at betale royalities og milepælsbetalinger til Neurosearch.

Bavarian og Janssen udvider samarbejde med ny millardaftale

Medicinal & Biotek:

Ny aftale giver Janssen eneret til Bavarian Nordic-teknologi inden for yderligere to vaccineudviklingsprogrammer. Aftalen kan indbringe det danske selskab op mod 879 mio. amerikanske dollars.

ANNONCE
ANNONCE


ANNONCE